Auliasari Meita Utami

Auliasari Meita Utami

Auto-generated profile, based on publicly available information

Auliasari Meita Utami

Center of Excellence for Pharmaceutical Care Innovation (PHARCI), Universitas Padjadjaran, Bandung, Indonesia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2022 in Journal of Multidisciplinary Healthcare
Verified
Journal Article
Open access
PDF file
AUAuliasari M Utami
Auliasari M Utami
Farida RendrayaniFarida Rendrayani
Farida Rendrayani
QKQisty A Khoiry
Qisty A Khoiry
FAFitri Alfiani
Fitri Alfiani
AKArif S W Kusuma
Arif S W Kusuma
ASAuliya Abdurrohim Suwantika
Auliya Abdurrohim Suwantika
Background: WHO reported that 5.5 million people died in the world because of COVID-19. One of the efforts to mitigate the pandemic is administrating the vaccines globally. Objective: The objective of this study was to review cost-effectiveness analysis of COVID-19 vaccination in low- and middle-income countries (LMICs). Methods: We searched PubMed and EBSCO for the eligible studies with inclusion criteria using cost-effectiveness analysis, free full text, low-middle-income countries, and the publication date since the last year. Four reviewers conducted the review independently. Results: The review identified four articles meeting the eligibility criteria. The settings were LMICs. Different perspectives and economic modelling used by the countries confirmed a similar result. They all explained that vaccination could prevent the infection spread and mortality caused by COVID-19 and showed high cost-effectiveness values. Conclusion: Administering COVID-19 vaccines was cost-effective and even cost-saving. The studies found that vaccination was more cost-effective in reducing the spread of the COVID-19 virus and the mortality it caused than no vaccination.

1 January 2024 in ClinicoEconomics and Outcomes Research
Verified
Journal Article
Open access
PDF file
SASanti Aprilianti
Santi Aprilianti
AUAuliasari M Utami
Auliasari M Utami
ASAuliya Abdurrohim Suwantika
Auliya Abdurrohim Suwantika
NZNeily Zakiyah
Neily Zakiyah
VAVanji Ikhsan Azis
Vanji Ikhsan Azis
The World Health Organization (WHO) recommends dolutegravir (DTG), a human immunodeficiency virus (HIV) medicine, as the first- and second-line treatment for all populations because, when compared to an efavirenz (EFV) regimen, plus two nucleoside reverse transcriptase inhibitors (NRTIs) has demonstrated significant effectiveness in HIV suppression in persons. This study aims to review evidence of the cost-effectiveness of DTG in combination with tenofovir and lamivudine compared with the standard of care for HIV therapy. The systematic review involved searching electronic databases for articles published between January 2018 and May 2022. Electronic database sources include PubMed, ScienceDirect, and EBSCO for articles on DTG in combination with tenofovir and lamivudine as subjects with cost-effectiveness outcomes. The inclusion criteria in this systematic review were studies about the cost-effectiveness analysis (CEA) of DTG in combination with tenofovir and lamivudine, written in English. A total of 145 articles were identified from three databases. After removing nine duplicates, 142 articles were screened by title and abstract, excluding 123 articles. After a full-text screening of 19 articles, five articles were selected for further analysis. Five articles reviewed in sub-Saharan Africa, India, and China implemented different modelling methods for CEA but produced similar results. The results of these studies demonstrate that it is more cost-effective than standard care for HIV treatment. The study conducted in sub-Saharan Africa from 2018 to 2020 showed a cost-effective result with disability-adjusted life years averted (DALY averted) by 83%; in India, it resulted in incremental cost-effectiveness ratio (ICER) $130 per year of live-saved (YLS); and a study in China found that dolutegravir plus tenofovir and lamivudine led to 0.006 incremental quality-adjusted life years (QALYs) with cost savings of $64. The DTG regimen is cost-effective and recommended for HIV therapy in all studies that provide results.

1 March 2025 in International Journal of Women's Health
Verified
Journal Article
Open access
PDF file
FAFitri Alfiani
Fitri Alfiani
AUAuliasari Meita Utami
Auliasari Meita Utami
NZNeily Zakiyah
Neily Zakiyah
NDNur Aizati Athirah Daud
Nur Aizati Athirah Daud
ASAuliya Abdurrohim Suwantika
Auliya Abdurrohim Suwantika
IPIrma Melyani Puspitasari
Irma Melyani Puspitasari
Introduction: Multiple micronutrient deficiencies might increase the adverse outcome during pregnancy and after birth. Considering the WHO recommendations since 2016 and scientific evidence from previous studies that multiple-micronutrient supplementation (MMS) is more effective than iron folic acid (IFA) in improving pregnant women’s health, it is imperative to conduct an economic evaluation to assess the cost-effectiveness of MMS compared with IFA. Methods: We conducted a systematic review from PubMed and Scopus to identify the cost-effectiveness analyses of MMS compared to IFA for pregnant women up to January 2024. Data extraction included specific study characteristics, input parameters, cost elements, cost-effectiveness results, and key drivers of uncertainty. This systematic review adhered to The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Results: After removing 111 duplicates and following the screening process on the title and abstract of 1201 records, resulting in 125 full-text articles assessed for eligibility, a total of 5 studies fulfilled the inclusion criteria and were included in the review. All included studies were from low- and middle-income countries and demonstrated that MMS compared to IFA for pregnant women is cost-effective and even very cost-effective in some countries. All included studies implemented cost-effectiveness analysis (CEA) and estimated its cost-effectiveness using incremental cost-effectiveness ratio (ICER) per disability-adjusted life years (DALY) averted. Results suggested that the transition from IFA to MMS was cost-effective. The range of ICER per DALY averted in this study is USD 3.62 to USD 1024, depending on the scenario. Overall, the main determinant influencing cost-effectiveness was the cost of MMS procurement. Conclusion: Our findings highlight that transitioning from IFA to MMS in certain conditions has been proven cost-effective, emphasizing this intervention’s economic viability. MMS price and micronutrient deficiency-related disease burden are important determinants in assessing cost-effectiveness. Registration: PROSPERO CRD42022319470.

1 November 2025 in ClinicoEconomics and Outcomes Research
Verified
Journal Article
Open access
PDF file
FAFitri Alfiani
Fitri Alfiani
AUAuliasari Meita Utami
Auliasari Meita Utami
NZNeily Zakiyah
Neily Zakiyah
NDNur Aizati Athirah Daud
Nur Aizati Athirah Daud
ASAuliya Abdurrohim Suwantika
Auliya Abdurrohim Suwantika
IPIrma Melyani Puspitasari
Irma Melyani Puspitasari
Introduction: The World Health Organization (WHO) has advocated for multiple micronutrient supplementation (MMS) for pregnant women since 2016 to mitigate the risk of various complications. As a country considering investment in MMS, Indonesia requires an assessment of the cost-effectiveness analysis and priority setting in the transition from IFA to MMS, which is essential in the decision-making process. Methods: An open-access online modelling tool was used to estimate the cost-effectiveness of MMS (ICERs per DALY averted) at national and sub-national levels (38 provinces) in Indonesia. The results were then prioritized via a cost-effectiveness league table, with a deterministic sensitivity analysis testing the robustness of the results. Results: Implementing MMS under 44% and 100% coverage scenarios has the potential to avert 54,897 and 124,766 DALYs in Indonesia, respectively, and produced an equivalent incremental cost-effectiveness ratio (ICER) value of USD 10 per DALY averted, which is regarded as highly cost-effective. Since costs and benefits scale linearly with coverage, ICER per DALY averted stays unchanged. The MMS program is recommended to be prioritized in 18 provinces having favorable ICERs, which are Southwest Papua, Highlands Papua, Bali, West Java, South Kalimantan, North Maluku, West Papua, Aceh, North Sumatra, Central Java, Central Kalimantan, West Sulawesi, Maluku, Yogyakarta, East Java, North Kalimantan, South Sulawesi, and South Papua. Related to the sensitivity analysis, the cost of MMS and IFA are the most significant variables influencing the ICER value. Conclusion: The findings show that the implementation of MMS, in comparison to IFA, produces a highly cost-effective outcome in 44% and 100% scenarios. The MMS implementation strategy may initiate with a 44% coverage scenario across 18 prioritized provinces, subsequently expanding to achieve 100% coverage for all pregnant women in Indonesia.